Process for updating the Handbook
For details on when and how updates to the Handbook are made, please see here.
- Handbook updates pending (August 2021)
- What's new in Handbook Version 6.2 (2021)
- What's new in Handbook Version 6.1 (2020)
- What's new in Handbook Version 6 (2019)
- What's new in Handbook version 5.2.0 (June 2017)
- What's new in Handbook version 5.1.0 (March 2011)
- What's new in Handbook version 5.0.2 (September 2009)
- What's new in Handbook version 5.0.1 (September 2008)
- What's new in Handbook version 5 (February 2008)
No updates pending.
- Section 1.3, ‘Declarations of interest’ subsection updated to reflect Cochrane’s new conflict of interest policy.
- Section III.3.7, ‘Declarations of interest’ subsection updated to reflect Cochrane’s new conflict of interest policy.
- Section 4.4.6 updated to clarify definitions for errata and retractions; two references added to the chapter; and small edits for formatting or readability edits that do not affect scientific content.
- Supplementary 1: Section 3.6.3 clarification that the search is optimised for CINAHL Plus; Section 3.7 updates to Box 3.g. search strategy for CENTRAL; Section 3.9 updates on searching for retractions; and small edits for formatting or readability edits that do not affect scientific content.
- Section 7.3.2, MECIR Box 7.3.c, C56: Highly desirable -changed to- C56: Mandatory
Only chapter 14 and 20 are reprinted as version 6.1, all other chapters remain as 6 versions.
Version 6.1 is available here.
14.2.2 Domains that can lead to decreasing the certainty level of a body of evidence: In each case, if a reason is found for downgrading the evidence, it should be classified as ‘no limitation’ (not important enough to warrant downgrading), ‘serious’ (downgrading the certainty rating by one level) or ‘very serious’ (downgrading the certainty grade by two levels). For non-randomized studies assessed with ROBINS-I, rating down by three levels should be classified as ‘extremely’ serious.
- changed to -
In each case, if no reason is found for downgrading the evidence, it should be classified as ‘no limitation or not serious’ (not important enough to warrant downgrading). If a reason is found for downgrading the evidence, it should be classified as ‘serious’ (downgrading the certainty rating by one level) or ‘very serious’ (downgrading the certainty grade by two levels). For non-randomized studies assessed with ROBINS-I, rating down by three levels should be classified as ‘extremely’ serious.
- Patricia Aluko is now the first and corresponding author for Chapter 20 on economic evidence, and Ian Shemilt has stepped down as co-author. This change is reflected in the new authorship list and citation of the Chapter.
Version 6 was a major revision of the Handbook, and virtually all of it was updated, revised or rewritten from Version 5. A PDF summary of the new material is available.
Version 6 is available (from Oct 1st, 2019) here.
Only chapters 1, 8, 9, 10, 11,12 and 21 are reprinted as version 5.2.0, all other chapters remain as 5.1.0 versions.
Version 5.2 is available here.
Where we refer to individual MECIR standards in the text, a symbol in the margin highlights the standard covered. Summary tables of all chapter relevant MECIR standards are at the end of each chapter. We have clarified terminology throughout these chapters where we refer to included ‘studies’ rather than ‘trials’.
- Various amendments for consistency with the comparable chapters in the Cochrane Handbook for Reviews of Diagnostic Test Accuracy.
- New Section 1.3 outlining the four kinds of Cochrane Reviews (intervention, diagnostic test accuracy, overviews and methodology).
- Old Section 1.4, ‘Contributors to the Handbook’ relocated to the Preface.
- Updated information on the Cochrane Library, including which databases are archived and no longer actively updated (Section 1.4).
- New Section 2.5 brings together updating information on Cochrane training, software and guidance on resources and funding. Information internal to Cochrane (such as the internal workings of Archie) has been removed.
- Includes a description of the feature in RevMan 5.3 allowing ‘Risk of bias’ assessments to be presented visually on forest plots (Section 8.6).
- Addition of recent empirical evidence (including from the BRANDO study) of the impact of random sequence generation on effect estimates (Section 8.9.1), allocation concealment (Section 8.10.1), blinding of participants and personnel (Section 8.11.1), blinding of outcome assessors (Section 8.12.1) and selective outcome reporting (Section 8.14.1).
- Additional text added to emphasize the importance of assessing incomplete outcome data separately for different outcomes or time points (Section 8.13.2).
- New Section 188.8.131.52 on issues that have been raised in relation to risk of bias, but for which the Handbook is unable to provide definitive guidance at present, including the influence of funders, early stopping, and single-centre versus multi-centre studies.
- New Section 184.108.40.206 on the importance of checking data before completing a synthesis, including checking the magnitude and direction of effect in the synthesis against the original study data. This can avoid several possible problems, including errors in the published data, data collection, any calculations or manipulation of data, and data entry into RevMan.
- Additional emphasis on the importance of considering missing participant data and its impact on meta-analysis (Section 9.4.2).
- Additional emphasis on the uncertainty of estimating the I2 statistic to quantify heterogeneity when the number of studies in a meta-analysis is small (Section 9.5.2).
- Clarification that it is It is a mistake to compare within-subgroup inferences such as P values to test for a significant difference between subgroups, and that a formal statistical test to compare subgroups should be used (Section 220.127.116.11).
- Change in terminology from ‘baseline risk’ to the preferred ‘underlying risk’ when discussing possible sources of heterogeneity (Section 9.6.7).
- Provides updated evidence on the prevalence of reporting bias from studies of FDA data (Section 10.2.1), the peer review process (Section 10.2.1.2), industry documents made available after legal challenges (Section 10.2.1.3), and the publication of positive trials in prestigious journals (Section 10.2.2.2).
- Includes a recommendation to search systematically for unpublished trial data, including a brief discussion of sources (Section 10.3.2).
- Notes that the Clinicaltrials.gov trials register now requires preliminary results to be posted within one year of the study’s completion (Section 10.3.3).
- Notes that the minimum number of trials required to generate a funnel plot with adequate power to detect asymmetry may be considerably higher than 10 in some circumstances. (Section 10.4.3.1).
- New Section 10.4.4.7 discusses regression methods for dealing with potential reporting biases.
- Title changed from ‘Presenting results and ‘Summary of ‘Findings’ Tables’ to ‘Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence’.
- Old introduction removed (Section 11.1)
- Old Section 11.2 ‘Reporting the results of the search’, including PRISMA flow diagrams and the ‘Characteristics of included studies’ table, has been removed. This content will be incorporated into updated chapters on searching and reporting the review in Version 6 of the Handbook.
- Old Section 11.3 ‘Data and analyses’, including the ‘Data ans analyses’ section of a review, forest plots and other data tables has been removed. This content will be incorporated into anew chapters on meta-analysis and reporting the review in Version 6 of the Handbook.
- Specifically lists the footnotes as an essential component of a SoF table (Section 11.1.3)
- Updated to refer to the new SoF software, GRADEpro GDT (Section 11.1.4)
- Table 11.2.e ‘Judgements about indirectness by outcome’ added, based on GRADEpro GDT, to assist authors in assessing the indirectness of the evidence in their review in relation to the question originally asked.
- Further guidance included about the use of the Optimal Information Size (OIS) in assessing the imprecision of a body of evidence (Section 11.2.2).
- New section 11.2 ‘Assessing the quality of a body of evidence’, including guidance on GRADE, moved here from Chapter 12.
- New Section 11.3 Describing the assessment of the quality of a body of evidence using the GRADE framework, providing guidance on how to express justifications for downgrading or upgrading the quality of the body of evidence using the GRADE approach.
- Greater clarity on terminology used e.g. generalisability and numbers needed to treat.
- Old section 12.2 ‘Assessing the quality of a body of evidence’, including guidance on GRADE, moved to Chapter 11.
- Extended Section 12.6 on implications for research with an additional table 12.6a providing a structured approach to the interpretation of the quality of a body of evidence according to individual GRADE criteria.
Please note this chapter will be replaced by and integrated into at least two new chapters in Version 6: Issues of Equity and Specific populations, and Complex Interventions.
- Greater clarity defining public health and health promotion interventions emphasizing population level rather than individual level intervention are of interest that operate within a broader context.
- Database table at 21.3 is updated
- Section 21.4 on assessment of study quality and risk of bias is updated.
- At section 21.7 additional frameworks are added to assist in determining sustainability
A PDF summary of these changes is also available.
Version 5.1 is available here.
- Section 1.1.3: The publication frequency of the CDSR has been updated (from quarterly to monthly).
- Section 2.3.6: Reference to the training web site and open learning modules has been updated.
- Box 3.2.c and Section 18.104.22.168: Criterion 5 (Accumulation of changes) for creating a new citation version has been relaxed slightly.
- Section 4.5 (Methods): A new section about planning a ‘Summary of findings’ table has been added.
- Section 4.5 (Results): A reference PRISMA flow diagrams has been inserted under ‘Results of the search’.
- Section 4.5 (Discussion): The section on ‘Quality of the evidence’ has been amended to refer to ‘Summary of findings’ tables and GRADE assessments.
- Section 4.7.2: Guidance on referring to ‘Other published versions of this review’ has been clarified. As a general rule, only new citation versions of publications in the CDSR should be listed (i.e. those that yield a new MEDLINE record).
- Table 4.9.a and Section 4.9.1: Two new types of RevMan Figure have been added: RevMan study flow diagram (PRISMA template) and RevMan flow diagram.
- Section 5.4.1: Guidance about using outcomes as criteria for including studies has been clarified, including advice against using a lack of ‘usable’ data as a criterion.
- Section 6.6.1: Advice to document the search results has been added in anticipation of a PRISMA flow diagram.
- Section 6.6.2: Clarity has been added that the search methods should be presented in a protocol, even if the detailed (line by line) search strategy is not.
- The Cochrane ‘Risk of bias tool’ has been modified for RevMan 5.1. The chapter has been modified in numerous places to reflect the modified tool. The changes are summarized in Table 8.5.b. The main alterations are in sections 8.4, 8.5, 8.6, 8.8.3, 8.11, 8.12 [new] and 8.15.
- The chapter’s editors are now Higgins JPT, Altman DG and Sterne JAC.
- Section 22.214.171.124: A more general version of the test for differences between subgroups is now described, as it has been implemented in RevMan.
- Figure 10.4.c: The figure has been corrected.
- Section 11.2: A new section about PRISMA study flow diagrams has been introduced.
- Section 11.5.3: The text of bullet point 5 has been modified slightly to clarify the purpose of GRADE.
- Section 11.5.4: A comment has been inserted to point out the context-specific help file in GRADEpro.
Version 5.0.2 is available here.
- Boxes 6.4.a, 6.4.b, 6.4.c, 6.4.d : last lines of each strategy corrected.
- Table 13.2.b: Entries for ITS and ChBA have been corrected for the first two rows.
- Reference added for Hollis 1999 (was missing from browseable version only).
- Extensive copy editing for style, spelling and grammar.
- Section 126.96.36.199: Clarification that updated reviews are flagged with a ‘New search’ flag in CDSR.
- Section 3.5.2: Clarification that withdrawn reviews should be given an ‘Amended’ event in the ‘What’s new’ table.
- Section 4.5: Added “Review authors who wish to mix recommended with optional subheadings should ensure that they are all displayed in appropriately consistent styles, which may require deactivating all of the recommended headings embedded in RevMan and creating them manually.”
- Section 188.8.131.52: Added mention of Section 801 of the Food and Drug Administration Amendments Act of 2007.
- Section 184.108.40.206: Search strategy in 2nd paragraph rephrased
- Section 6.4.11: Added mention of search filter appraisal tool.
- Boxes 6.4.a, 6.4.b, 6.4.c, 6.4.d : Last two lines of each strategy corrected.
- Box 6.4.f: Lines 9 and 10 of search strategy corrected.
- Section 7.7.6: Added reference to Tierney 2007.
- Section 9.4.1: Added mention of supplementary document Statistical Algorithms in Review Manager 5.
- Section 9.5.4: Added reference for predictive intervals for random-effects meta-analysis.
- Section 220.127.116.11: Added “If there is an excessive number of outcomes in the review, authors will need to omit the less important outcomes.”
- Section 11.8: Clarified that trade names should not be used.
- Added new key point, “Quality ratings are made separately for each outcome”.
- Section 12.6.4: New discussion of source of standard deviations for interpreting SMDs.
- Section 13.1.2, item (e): Removed text “However, justifying a systematic review of NRS on the ground of supplementing randomized trial evidence may be acceptable if the available evidence from randomized trials is of such limited quantity or poor quality that NRS may actually provide better evidence.”
- Tables 13.2.a and 13.2.b: Added ‘Some other process (specify)? as an option for allocation to groups.
- Section 15.6.1: more information on Purchasing Power Parities and use of gross domestic product deflators.
- Added new key point, “There may be circumstances where the benefits of obtaining IPD are marginal; others where it could be vital.”
- Changed from “health promotion and public health” to “public health and health promotion”.
Version 5.0 is available here.
Version 5 was a major revision of the Handbook, and virtually all of it was updated, revised or rewritten from Version 4. A PDF summary of the new material is available.